Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia (Q28254349)

Nature Reviews Drug Discovery

Europe PubMed Central

title

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia (English)

0 references

0 references

1 reference

Bryan L Roth

1

0 references

Douglas J Sheffler

series ordinal

2

0 references

Wesley K Kroeze

series ordinal

3

0 references

language of work or name

English

0 references

publication date

April 2004

0 references

published in

0 references

volume

3

0 references

issue

4

0 references

page(s)

353-9

0 references

cites work

Looking backwards: a possible new path for drug discovery in psychopharmacology

1 reference

Correction: a note on the discovery of selective serotonin reuptake inhibitors

31 March 2020

1 reference

Genes for schizophrenia? Recent findings and their pathophysiological implications

31 March 2020

1 reference

Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia

31 March 2020

1 reference

Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants

31 March 2020

1 reference

Finding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments

31 March 2020

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

31 March 2020

1 reference

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

31 March 2020

1 reference

Discovering risperidone: the LSD model of psychopathology

31 March 2020

1 reference

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.

31 March 2020

1 reference

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

31 March 2020

1 reference

Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials

31 March 2020

1 reference

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

31 March 2020

1 reference

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

31 March 2020

1 reference

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

31 March 2020

1 reference

The physiological role of 5-HT2A receptors in working memory

31 March 2020

1 reference

A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze.

31 March 2020

1 reference

Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation

31 March 2020

1 reference

The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance

31 March 2020

1 reference

Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioral studies.

31 March 2020

1 reference

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia

31 March 2020

1 reference

Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia

31 March 2020

1 reference

Dopamine agonists in schizophrenia: a review

31 March 2020

1 reference

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

31 March 2020

1 reference

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

31 March 2020

1 reference

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

31 March 2020

1 reference

Efficacy at G-protein-coupled receptors

31 March 2020

1 reference

Multiple mechanisms of serotonergic signal transduction

31 March 2020

1 reference

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

31 March 2020

1 reference

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

31 March 2020

1 reference

Meta-analytical studies on new antidepressants.

31 March 2020

1 reference

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

31 March 2020

1 reference

Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression

31 March 2020

1 reference

In need of high-throughput behavioral systems

31 March 2020

1 reference

Animal models. Can a mouse be standardized?

31 March 2020

1 reference

A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A--a putative, new antidepressant

31 March 2020

1 reference

Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression.

31 March 2020

1 reference

Novel directions in antipsychotic target identification using gene arrays

31 March 2020

1 reference

Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole

31 March 2020

1 reference

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

31 March 2020

1 reference

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group

31 March 2020

1 reference

BMY 14802, a sigma receptor ligand for the treatment of schizophrenia

31 March 2020

1 reference

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

31 March 2020

1 reference

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

31 March 2020

1 reference

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

31 March 2020

1 reference

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

31 March 2020

1 reference

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

31 March 2020

1 reference

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment

31 March 2020

1 reference

The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial

31 March 2020

1 reference

31 March 2020

1 reference

G-protein-coupled receptors at a glance

31 March 2020

1 reference